Search for:
Search for:
Healthcare Professionals
Publications
Contact
News
Español
Magazine
Radio
*
INFÓRMESE
¿Qué es EM?
Un trastorno neurológico crónico que afecta el sistema nervioso central, compuesto por el cerebro...
Más detalles
MATERIALES EDUCATIVOS
PREGUNTAS COMUNES
Lending Library
Symptoms
Treatment Options
Additional Resources
INVESTIGACIÓN
MS Awareness Month
DONAR
OBTENGA AYUDA
Programa de Salud y Bi...
Obtenga materiales educativos y referencias así como también la oportunidad de participar en...
Más información
Grants & Programs
Awareness Campaigns
GRUPOS DE APOYO
Events
Lending Library
Additional Resources
PARTICIPE
Mes de Concientización...
Una campaña anual a nivel nacional con objetivos para promover la comprensión de la EM y ayudar a...
Más información
Advocacy
COMPRAS A SOCIOS
VOLUNTARIO
Businesses
MS Research Trials
Outreach
Supporter Program
Awareness Campaigns
Host an Event
Events
MS Focus on Fashion
The inaugural MS Focus on Fashion, will take place on Nov. 6, in Dania Beach, Fla.
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
QUIÉNES SOMOS
Programas y Subvenciones
Más detalles
Overview
Press Room
LIDERAZGO
ESTADOS FINANCIEROS
NUESTRA MISIÓN
Careers at MS Focus
Affiliations
News
PROGRAMA DE COMPUTADORA
El programa informático de MS Focus proporciona computadoras portátiles o de escritorio para...
/Get-Help/MSF-Programs-Grants/Computer-Program
Shop
Privacy
Terms of Use
Site Map
Molecular mechanisms linked to MS progression, severity, and type
febrero 27, 2023
A new study set out to identify pathways and upstream regulators that correlate with all measurable aspects of multiple sclerosis types, and to develop and validate cerebrospinal fluid biomarker-based models predicting disability and severity outcomes. The researchers found that compartmentalized inflammation and its effector mechanisms showed the strongest link to MS severity.
Current MS treatments target the immune system and lose their efficacy with the advancing patients’ age of therapy initiation. This has led to broad belief that neuroinflammation decreases with MS evolution and instead neurodegenerative mechanisms cause continuous central nervous system tissue destruction in progressive MS. Such late-disease mechanisms are inadequately reflected in acute and short-term animal models and up to this point were only investigated in postmortem human pathology studies.
Researchers at the National Institute of Allergy and Infectious Diseases, Frederick National Laboratory for Cancer Research, and Novartis Institutes for Biomedical Research analyzed nine prospectively acquired clinical and imaging outcomes in 176 relapsing-remitting and 215 progressive MS patients and 45 healthy volunteers, along with matched cellular and more than 5,000 protein data in 1,042 CSF samples. CSF proteins significantly correlated with the MS outcomes were evaluated by Ingenuity Pathway Analysis to uncover MS-related biology. Machine learning algorithms were employed to generate and independently validate CSF protein-based models predicting nine MS outcomes.
The researchers found that compartmentalized inflammation and its effector mechanisms, such as pyroptosis, showed the strongest link to MS severity, irrespective of clinical categorization of patients. Humoral responses and viral infection-related pathways were linked only to disease severity, not with MS progression. Moreover, localization of the CNS injury showed distinct molecular signatures. While patients with predominant brain injury showed proportionally higher levels of neuroinflammation, spinal cord involvement was reflected by increased fibrosis and tissue hypoxia. CNS-related processes, such as synaptogenesis, were beneficial and no inflammation-unrelated neurodegeneration was identified. CSF biomarker-based ML models predicted nine clinical and imaging outcomes with independently validated performance that exceeds all previously published MS models.
Proteomic data collected from minute volume of CSF reflects diverse molecular processes previously identified only by CNS biopsies or autopsies, and reliably predicts all currently measurable phenotypical aspects of MS in living subjects.
The study was presented at the 2023 ACTRIMS forum.
[Error loading the control 'FeaturedNews', check event log for more details]